O53. Efficacy and Safety of Tocilizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: 2 Year Data from Cherish

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticularcourse juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH F De Benedetti, N Ruperto, Z Zuber, R Cuttica, R Xavier, I Calvo, N Rubio, E Alekseeva, V Chasnyk, J Chavez, G Horneff, V Opoka-Winiarska, P Quartier, A Spindler, C Keane, K Bharucha, J Wang, D Lovell, A Martini, HI Brunner, PRINTO and PRCSG

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

OBJECTIVE To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). METHODS This three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received ...

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis

Methods The study enrolled 54 pediatric patients with polyarticular JIA, 32 of them received etanercept and 22 received abatacept. The demographic parameters were well matched across treatment groups. The mean age of children was 10.8 ± 3.7, the age at the disease onset was 5.4 ± 3.4, most of the patients were female. Prior to biological DMARD administration, all the subjects received multiple ...

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis

Results A total of 39 patients (21 boys and 18 girls) were included in this Median age was 7,5 years (range; 3 to 15 years) and median disease duration was 4,2 years (range; 0.5 to 8,3 years). A total of 16 of the 39 patients (25%) entered 52 weeks of continuous tocilizumab treatment. The frequently observed non-severe adverse events were nasopharyngitis, upper respiratory tract infection and g...